Effect of Human Recombinant Erythropoietin on Bleeding Time, Platelet Number and Function in Children with End-stage Renal Disease Maintained by Haemodialysis

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 1991 Mar 1

PMID 2031840

Citations 9

Authors

F Fabris

I Cordiano

M L Randi

A Casonato

G Montini

G Zacchello

A Girolami

Affiliations

Soon will be listed here.

Abstract

We studied platelet number and function in nine anaemic children with end-stage renal disease during a clinical trial with recombinant human erythropoietin (rHu-EPO). All the children showed a correction in both haematocrit and haemoglobin levels which was followed by a significant reduction in bleeding time. We also observed a significant increase in platelet count after both 6 and 12 weeks of therapy; at the same time mean platelet volume decreased and a normal platelet mass was maintained. The mean baseline platelet aggregation response to ADP was normal, but was decreased to collagen (P less than 0.05 vs normal control). Platelet production of thromboxane B2 in serum was also lower than normal controls. After correction of anaemia with rHu-EPO, platelet aggregation improved in patients with a decreased baseline response, and mean levels of thromboxane B2 became normal. In conclusion, the treatment with rHu-EPO improved haemostatic balance not only by correcting anaemia, but also by increasing platelet count and function.

Citing Articles

Differential Effects of Erythropoietin Administration and Overexpression on Venous Thrombosis in Mice.

Stockhausen S, Kilani B, Schubert I, Steinsiek A, Chandraratne S, Wendler F Thromb Haemost. 2023; 124(11):1027-1039.

PMID: 37846465 PMC: 11518618. DOI: 10.1055/s-0043-1775965.

Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review.

Bruce G, Schulga P, Reynolds B Clin Kidney J. 2022; 15(8):1483-1505.

PMID: 35892014 PMC: 9308099. DOI: 10.1093/ckj/sfac058.

Surgical Treatment for Non-Small Cell Lung Cancer in Patients on Hemodialysis due to Chronic Kidney Disease: Clinical Outcome and Intermediate-Term Results.

Park B, Shin S, Kim H, Choi Y, Kim J, Shim Y Korean J Thorac Cardiovasc Surg. 2015; 48(3):193-8.

PMID: 26078926 PMC: 4463229. DOI: 10.5090/kjtcs.2015.48.3.193.

Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS.

Seikaly M, Ho P, Emmett L, Fine R, Tejani A Pediatr Nephrol. 2003; 18(8):796-804.

PMID: 12811650 DOI: 10.1007/s00467-003-1158-5.

Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Whittington R, Barradell L, Benfield P Pharmacoeconomics. 1992; 3(1):45-82.

PMID: 10146987 DOI: 10.2165/00019053-199303010-00006.

References

Van Geet C, Hauglustaine D, Verresen L, Vanrusselt M, Vermylen J . Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost. 1989; 61(1):117-21. View

Winearls C, Oliver D, Pippard M, Reid C, Downing M, COTES P . Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986; 2(8517):1175-8. DOI: 10.1016/s0140-6736(86)92192-6. View

Di Minno G, Martinez J, McKean M, De la Rosa J, Burke J, Murphy S . Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med. 1985; 79(5):552-9. DOI: 10.1016/0002-9343(85)90051-8. View

Thompson C, Jakubowski J . The pathophysiology and clinical relevance of platelet heterogeneity. Blood. 1988; 72(1):1-8. View

Hill R, Levin J . Regulators of thrombopoiesis: their biochemistry and physiology. Blood Cells. 1989; 15(1):141-66. View

Eschbach J . The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35(1):134-48. DOI: 10.1038/ki.1989.18. View

Remuzzi G, Cavenaghi A, MECCA G, Donati M, de Gaetano G . Prostacyclin-like activity and bleeding in renal failure. Lancet. 1977; 2(8050):1195-7. DOI: 10.1016/s0140-6736(77)90437-8. View

Eschbach J, Egrie J, Downing M, Browne J, Adamson J . Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316(2):73-8. DOI: 10.1056/NEJM198701083160203. View

Luzzatto G, Fabris F, Mazzucato M, Girolami A . PF 4 versus beta TG as evidence for platelet activation in myeloproliferative disorders. Scand J Haematol. 1985; 35(3):299-304. DOI: 10.1111/j.1600-0609.1985.tb01709.x. View

10.

Luzzatto G, De Franchis G, Fabris F, Gerunda G, Girolami A . Increased proportion of giant platelets and platelet distribution width are better indicators of altered platelet homeostasis than mean platelet volume in liver cirrhosis. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988; 115(5):719-26. View

11.

Ishibashi T, Koziol J, BURSTEIN S . Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest. 1987; 79(1):286-9. PMC: 424045. DOI: 10.1172/JCI112796. View

12.

Steiner R, Coggins C, Carvalho A . Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979; 7(2):107-17. DOI: 10.1002/ajh.2830070203. View

13.

RABINER S . The effect of dialysis on platelet function of patients with renal failure. Ann N Y Acad Sci. 1972; 201:234-42. DOI: 10.1111/j.1749-6632.1972.tb16301.x. View

14.

Fabris F, Randi M, Sbrojavacca R, Casonato A, Girolami A . The possible value of platelet aggregation studies in patients with increased platelet number. Blut. 1981; 43(5):279-85. DOI: 10.1007/BF00320951. View

15.

Remuzzi G . Bleeding in renal failure. Lancet. 1988; 1(8596):1205-8. DOI: 10.1016/s0140-6736(88)92019-3. View

16.

Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, de Gaetano G . Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest. 1983; 71(3):762-8. PMC: 436927. DOI: 10.1172/jci110824. View

17.

Thompson C, Jakubowski J, Quinn P, Deykin D, Valeri C . Platelet size and age determine platelet function independently. Blood. 1984; 63(6):1372-5. View

18.

Bloom A, Greaves M, Preston F, Brown C . Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol. 1986; 62(1):143-9. DOI: 10.1111/j.1365-2141.1986.tb02910.x. View

19.

Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, SUC J . Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol. 1985; 59(1):139-48. DOI: 10.1111/j.1365-2141.1985.tb02974.x. View

20.

Bommer J, Ritz E, Eifert J . Recombinant human erythropoietin in anaemic patients on haemodialysis. Lancet. 1987; 1(8529):392. DOI: 10.1016/s0140-6736(87)91774-0. View